This article is intended to offer a broad overview of the medical device regulatory landscape in India rather than a detailed legal or technical analysis. For device-specific or situation-specific guidance, readers are encouraged to reach out to us directly with their information needs.

India’s medical device ecosystem has shifted from a largely unregulated space to a tightly governed, quality-driven market anchored in MDR 2017 under the Drugs and Cosmetics Act, 1940. For manufacturers, importers, and innovators, understanding this framework is now a strategic necessity rather than a compliance formality.

Why India’s Device Regulations Matter

• India is one of the fastest-growing MedTech markets, attracting both domestic startups and global manufacturers.
• Regulatory expectations increasingly mirror global best practices, with greater emphasis on patient safety, transparency, and life-cycle oversight.

Core Regulatory Architecture

The Indian regime builds on a clear legal and institutional structure that defines how devices are classified, approved, and monitored.

Legal Basis and Key Instruments

• Drugs and Cosmetics Act, 1940: Provides the overarching legal foundation under which medical devices are treated as a specific regulatory category.
• Medical Devices Rules, 2017 (MDR 2017): Establish a dedicated, risk-based framework covering manufacture, import, sale, distribution, clinical investigation, and post-market activities.
• Periodic notifications, FAQs, and guidance documents from CDSCO refine interpretation and expectations on topics such as labelling, SaMD, and risk classification.

Institutional Setup: Central vs State Roles

India follows a dual-layer regulatory model for devices.

• Central Licensing Authority (CDSCO)
  • Grants licences for import and for higher-risk devices (Class C and D).
  • Oversees clinical investigations, post-market vigilance, and certain high-impact IVDs.
• State Licensing Authorities (SLAs)
  • Handle manufacturing and sale licences for lower-risk devices (Class A and B).

Risk-Based Classification and Pathways

Device Risk Classes

• Class A – Low risk.
• Class B – Low to moderate risk.
• Class C – Moderate to high risk.
• Class D – High risk.

Licensing Pathways and Forms

• Import: Application via Form MD-14 and grant of licence in MD-15.
• Manufacturing: Applications in MD-7 / MD-8 and approvals through MD-9 / MD-10.
• Test / Evaluation: Test licences (MD-16 / MD-17).

Foreign manufacturers must appoint an Authorized Indian Agent to interface with CDSCO.

Technical Documentation and QMS Expectations

• Device Master File (DMF).
• Plant Master File (PMF).
• ISO 13485-based quality systems.

Digitalization, SaMD, and Recent Updates (2024–2026)

Expansion of Regulated Scope

• All medical devices and IVDs are now regulated.
• Class A devices have streamlined requirements.

Online Portals and Process Efficiency

• SUGAM portal improves submission and tracking.
• New tools reduce duplication and improve speed.

FAQs and Clarifications

• Clarifications on labelling, imports, outsourcing, etc.

Software as a Medical Device (SaMD)

• Software classification based on risk and intended use.
• Cybersecurity and AI/ML oversight.

Compliance Challenges and Strategic Opportunities

Key Compliance Pain Points

• Changing regulatory interpretations.
• State-level variability.
• SME challenges.

Emerging Opportunities

• Global harmonisation.
• Digital health and SaMD growth.
• Make in India and export readiness.

Takeaways

• Treat MDR 2017 as a living framework.
• Invest early in documentation and QMS.
• Plan regulatory strategy for SaMD early.

References

• CDSCO – Medical Devices Rules, 2017
• CDSCO – Risk Classification Lists
• Industry publications and guidance documents